甲虫剂麦克洛纳泽帕姆激活了一个类分裂体的短暂受体潜在通道
Sang-Kyu Park1, Daniel J Sprague2, Claudia M Rohr1
1Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
The Journal of biological chemistry
|December 3, 2023
概括
新的研究确定了一种特定的离子通道,TRPMMCLZ,作为寄生虫平虫中麦克洛纳泽巴姆 (MCLZ) 的标. 这一发现为开发新型杆菌病药物提供了一个新的目标,有可能克服对当前治疗方法的耐药性.
科学领域:
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 疏忽的热带疾病 - - istosomiasis,对全球健康造成重大负担.
- 目前的治疗依赖于普拉齐昆 (PZQ),它有局限性,包括对幼虫的疗效不佳.
- 梅克洛纳泽帕姆 (MCLZ) 显示对幼虫的有效性,但具有宿主副作用和未知的寄生虫点.
研究的目的:
- 在寄生虫平虫中识别梅克洛纳泽 (MCLZ) 的分子标.
- 描述MCLZ及其目标之间的相互作用.
- 探索这个点在开发新的抗杆菌病药物方面的潜力.
主要方法:
- 生物化学分析以确定药物标.
- 电生理学研究离子通道活性.
- 基因分析用于调查目标多态性.
主要成果:
- 鉴定了一种梅拉斯塔丁子家族的短暂受体潜在离子通道,TRPMMCLZ,作为Schistosoma mansoni中的MCLZ的标.
- MCLZ通过结合电压传感器类域中的一个口袋来激活TRPMMCLZ,导致麻和损伤.
- TRPMMCLZ与PZQ目标 (TRPMPZQ) 是不同的,表明不同的作用机制.
结论:
- TRPMMCLZ是一种新的,可用药物治疗的抗杆菌病治疗标.
- 针对TRPMMCLZ可以克服对PZQ等现有药物的耐药性.
- 了解这个目标有助于合理设计新型杀虫剂的药物.
相关概念视频
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
266
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
266
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
684
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
684
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
01:28Depolarizing Blockers: Mechanism of Action
1.6K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.6K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
314
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
314